SNPHY logo
Santen Pharmaceutical Co., Ltd.(SNPHY)
Closing price · checked 11:13 PM ETAbout this dataData status
$12.50▼-0.06 (-0.48%)
Extended:$12.50+0.00 (+0.00%)· 11:13 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Santen Pharmaceutical Co., Ltd. (SNPHY)

Stock Repurchases

-¥4.92B

TTM · Period ending: · JPY

SNPHY logo

SNPHY Stock Repurchases

Latest reported-¥4.92B JPY
SNPHY Stock Repurchases · JPY (-¥2.58B → -¥4.92B)
High-resolution chart · PNG

What is stock repurchases?

Cash used to repurchase common stock.

SNPHY stock repurchases history

Annual fiscal periods · JPY. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

Santen Pharmaceutical Co., Ltd. Stock Repurchases — Annual fiscal periods (JPY)
Period endingStock Repurchases (JPY)Change
-34,774,916,000—
-37,883,000,000—
-16,962,000,000—
-26,007,000,000—
-12,000,000—
0—
-22,000,000—
-14,124,000,000—
-1,000,000—
-12,380,000,000—
-5,000,000—
0—
-6,000,000—
-13,764,000,000—
-2,000,000—
-25,000,000—
-24,000,000—
-15,000,000—
-4,815,000,000—
-16,000,000—
-15,000,000—
-2,582,000,000—

Frequently asked questions: SNPHY stock repurchases

What is Santen Pharmaceutical Co., Ltd. (SNPHY)'s current stock repurchases?

Santen Pharmaceutical Co., Ltd. (SNPHY)'s latest reported stock repurchases (TTM) is -¥4.92B as of Sep 30, 2026. Cash used to repurchase common stock.

How much historical stock repurchases data is available for SNPHY?

Stock Alarm Pro provides 22 dated annual fiscal periods observations for Santen Pharmaceutical Co., Ltd. (SNPHY)'s stock repurchases, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare SNPHY's stock repurchases to peers or set an alert?

You can open SNPHY's stock repurchases in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on SNPHY delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.